capivasertib
AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial
AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN